Purple Biotech Ltd PPBT

PPBT Company Overview

Purple Biotech Ltd. is a clinical-stage biotechnology company focused on developing therapies for cancer treatment, with an emphasis on overcoming tumor immune evasion and drug resistance mechanisms. The company operates within the oncology and immuno-oncology sectors and is publicly traded on Nasdaq under the ticker PPBT and on the Tel Aviv Stock Exchange. Its core activities center on advancing proprietary therapeutic candidates through clinical development, particularly monoclonal antibodies and targeted oncology therapies designed to improve outcomes in difficult-to-treat cancers.

The company’s primary value drivers are its clinical-stage oncology assets, including CM24, a monoclonal antibody targeting CEACAM1, and NT219, a dual inhibitor targeting STAT3 and IRS1/2 signaling pathways associated with cancer resistance. Purple Biotech evolved from earlier biotechnology operations in Israel and rebranded from Kitov Pharma Ltd. following strategic acquisitions and pipeline restructuring intended to concentrate the business on oncology innovation. The company’s positioning is tied to its focus on combination therapies and novel immune-modulating approaches that may complement existing checkpoint inhibitor treatments.